Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

43.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.1K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

14.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Subviral Agents01:29

Subviral Agents

940
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
940
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

73
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73
Anthelminthic Agents01:15

Anthelminthic Agents

115
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
115

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Total Synthesis of Pedopeptin C.

Organic letters·2025
Same author

Lipid Tales: Optimizing Arylomycin Membrane Anchors.

ACS medicinal chemistry letters·2023
查看所有相关文章

相关实验视频

Updated: May 6, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 12, 2013

13.7K

开发冠状病毒抗病毒药物的冲刺.

Michael F T Koehler1

  • 1Department of Discovery Chemistry, Genentech Inc., South San Francisco, California 94080, United States.

Journal of medicinal chemistry
|March 28, 2025
PubMed
概括

尼尔马特里尔维尔 (PF-07321332) 的发现是通过药物化学迅速实现的. 这导致了帕克斯洛维德的紧急使用授权,使得迅速的治疗选择.

科学领域:

  • 药用化学 医学化学
  • 药物发现 药物发现 药物发现
  • 抗病毒疗法 抗病毒疗法

背景情况:

  • 迫切需要有效的抗病毒治疗,需要快速发现和开发药物.
  • 临床前研究是识别和优化候选药物的关键阶段.

研究的目的:

  • 详细介绍PF-07321332 (nirmatrelvir) 发现背后的临床前研究和药物化学策略.
  • 要突出从项目启动到监管授权的加速时间表.

主要方法:

  • 化合物的药用化学优化.
  • 基于结构的药物设计原则.
  • 综合性临床前发展途径.

主要成果:

  • 成功识别和优化PF-07321332 (尼马特里尔维尔) 作为一种强大的抗病毒药物.
  • 在不到两年的时间里获得了Paxlovid的紧急使用授权 (EUA).
  • 通过战略规划和执行,证明了快速药物开发的可行性.

结论:

  • 药物化学是加速新疗法发现的关键.
  • 有效的临床前开发可以显著缩短药物授权的时间表.

更多相关视频

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.9K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.5K

相关实验视频

Last Updated: May 6, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 12, 2013

13.7K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.9K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.5K
  • 尼尔马特里尔维尔的开发是成功快速响应关键健康需求的一个例子.